BioSpace News Archive

Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, is expanding the Company’s medical and operational capabilities with four senior appointments.

ReCor Medical, Inc. and Otsuka Medical Devices Co., Ltd. announced that the RADIANCE II US FDA IDE pivotal trial evaluating the Paradise™ Ultrasound Renal Denervation System as a treatment for hypertension met its primary efficacy endpoint, demonstrating a statistically significant reduction in daytime ambulatory systolic blood pressure between treatment and a sham procedure measured at two months.

Astellas Pharma Inc. and Seagen Inc. announced positive topline results from the phase 1b/2 EV-103 clinical trial Cohort K evaluating PADCEV® in combination with Merck’s anti-PD-1 therapy KEYTRUDA® as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.

In a challenging macroeconomic environment, 3M executed well and delivered solid earnings, while continuing to drive growth through investments in large, fast-growing areas.

IVERIC bio, Inc. announced that it has entered into a term loan debt financing facility with Hercules Capital, Inc. and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-dilutive debt financing.

IVERIC bio, Inc. announced financial and operating results for the second quarter ended June 30, 2022 and provided a general business update.

Kelun-Biotech announced that it has entered into a collaboration and exclusive license agreement with MSD, to develop an investigational antibody drug conjugate for the treatment of solid tumors.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25.

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2022.

Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it is presenting about the utility of its multi-pathogen (“ multiplex ”) and swab-formatted Quality Assessment Products (“ QAPs™ ”) to monitor molecular assays that detect and distinguish between four sexually-transmitted infections (each an “ STI ”) that cause Genital Ulcer Disease (“ GUD ”) – at the 2022 conference.